Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, has been reported to promote cardioprotection in diabetic hearts by limiting hyperglycemia and hyperlipidemia. However, little is known about the involvement of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway modul...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Rasheed, Nouf M, Al-Rasheed, Nawal M, Hasan, Iman H, Al-Amin, Maha A, Al-Ajmi, Hanaa N, Mahmoud, Ayman M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933570/
https://www.ncbi.nlm.nih.gov/pubmed/27418808
http://dx.doi.org/10.2147/DDDT.S109287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933570/
https://www.ncbi.nlm.nih.gov/pubmed/27418808
http://dx.doi.org/10.2147/DDDT.S109287

Ejemplares similares